Area of research
Immunology · Dermatology
Research interest
Research interests include Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Spondyloarthritis Studies and Treatments, and Asthma and respiratory diseases.
S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations
A comprehensive, tri‐national, cross‐sectional analysis of characteristics and impact of pruritus in psoriasis
German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations
German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations
Deutsche S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 1: Therapieziele und Therapieempfehlungen
Skin Sodium Accumulates in Psoriasis and Reflects Disease Severity
Deutsche S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität
Biologics for atopic diseases: Indication, side effect management, and new developments
Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label <scp>CADMUS</scp> Jr study
Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019
S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 1
S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 2
S2k‐Leitlinie zur Therapie der Psoriasis bei Kindern und Jugendlichen – Kurzfassung Teil 2
S2k‐Leitlinie zur Therapie der Psoriasis bei Kindern und Jugendlichen – Kurzfassung Teil 1
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
S3‐Leitlinie zur Therapie der Psoriasis vulgaris Update – Kurzfassung Teil 1 – Systemische Therapie
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study
S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations
Application of Photoacoustic Methods and Confocal Microscopy for Monitoring of Therapeutic Response in Plaque Psoriasis
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Safety of Systemic Agents for the Treatment of Pediatric Psoriasis
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but Not with Loss-of-Function Mutations in IL36RN in European Patients
One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the <scp>TRANSIT</scp> randomized trial in moderate‐to‐severe plaque psoriasis
S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update
German S3-guidelines on the treatment of psoriasis vulgaris (short version)